

Elizabeth R Unger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3796537/publications.pdf>

Version: 2024-02-01

279
papers

15,580
citations

25034

57
h-index

20961

115
g-index

282
all docs

282
docs citations

282
times ranked

12256
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence of Human Papillomavirus Among Women Older than Recommended Age for Vaccination by Birth Cohort, United States 2003–2016. <i>Journal of Infectious Diseases</i> , 2022, 225, 94-104.	4.0	2
2	Sensitivity of Self-Reported Human Papillomavirus Vaccination History Among 18- to 26-Year-Old Men Who Have Sex With Men: Seattle, WA, 2016 to 2018. <i>Sexually Transmitted Diseases</i> , 2022, 49, 81-85.	1.7	11
3	Effectiveness of Human Papillomavirus (HPV) Vaccination Against Penile HPV Infection in Men Who Have Sex With Men and Transgender Women. <i>Journal of Infectious Diseases</i> , 2022, 225, 422-430.	4.0	11
4	High-Grade Vulvar, Vaginal, and Anal Precancers Among U.S. Adolescents and Young Adults After Human Papillomavirus Vaccine Introduction. <i>American Journal of Preventive Medicine</i> , 2022, 62, 95-99.	3.0	8
5	Cervical Precancers and Cancers Attributed to HPV Types by Race and Ethnicity: Implications for Vaccination, Screening, and Management. <i>Journal of the National Cancer Institute</i> , 2022, 114, 845-853.	6.3	12
6	Physiological assessment of orthostatic intolerance in chronic fatigue syndrome. <i>Journal of Translational Medicine</i> , 2022, 20, 95.	4.4	14
7	Changes in Cervical Cytology Results and Human Papillomavirus Types Among Persons Screened for Cervical Cancer, 2007 and 2015–2017. <i>Journal of Lower Genital Tract Disease</i> , 2022, 26, 135-139.	1.9	2
8	A community intervention effectiveness study of single dose or two doses of bivalent HPV vaccine (CERVARIX®) in female school students in Thailand. <i>PLoS ONE</i> , 2022, 17, e0267294.	2.5	5
9	Human Papillomavirus Vaccine Impact and Effectiveness Through 12 Years After Vaccine Introduction in the United States, 2003 to 2018. <i>Annals of Internal Medicine</i> , 2022, 175, 918-926.	3.9	20
10	Estimated Prevalence and Incidence of Disease-Associated Human Papillomavirus Types Among 15- to 59-Year-Olds in the United States. <i>Sexually Transmitted Diseases</i> , 2021, 48, 273-277.	1.7	48
11	NanoString Technology for Human Papillomavirus Typing. <i>Viruses</i> , 2021, 13, 188.	3.3	2
12	Significant Declines in Juvenile-onset Recurrent Respiratory Papillomatosis Following Human Papillomavirus (HPV) Vaccine Introduction in the United States. <i>Clinical Infectious Diseases</i> , 2021, 73, 885-890.	5.8	23
13	Declines in Prevalence of Human Papillomavirus Vaccine-Type Infection Among Females after Introduction of Vaccine – United States, 2003–2018. <i>Morbidity and Mortality Weekly Report</i> , 2021, 70, 415-420.	15.1	56
14	Human Papillomavirus Oral- and Sero- Positivity in Fanconi Anemia. <i>Cancers</i> , 2021, 13, 1368.	3.7	3
15	Genital Human Papillomavirus Prevalence Over the Lifespan Among Females and Males in a National Cross-Sectional Survey, United States, 2013–2016. <i>Sexually Transmitted Diseases</i> , 2021, 48, 855-863.	1.7	0
16	Juvenile-Onset Recurrent Respiratory Papillomatosis in the United States, <i>Epidemiology and HPV Types</i> – 2015–2020. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, 774-781.	1.3	12
17	Prevalence of human papillomavirus genotypes in high-grade cervical precancer and invasive cervical cancer from cancer registries before and after vaccine introduction in the United States. <i>Cancer</i> , 2021, 127, 3614-3621.	4.1	2
18	Increases in Human Papillomavirus Testing Preceding Diagnosis of Cervical Precancer in 5 US States, 2008–2016. <i>Journal of Lower Genital Tract Disease</i> , 2021, 25, 192-198.	1.9	2

#	ARTICLE	IF	CITATIONS
19	Human Papillomavirus Persistence and Association With Recurrent Cervical Intraepithelial Neoplasia After Cryotherapy vs Loop Electrosurgical Excision Procedure Among HIV-Positive Women. <i>JAMA Oncology</i> , 2021, 7, 1514.	7.1	4
20	Sexual Positioning Practices and Anal Human Papillomavirus Infection Among Young Men Who Have Sex with Men and Transgender Women—Chicago, Illinois, 2016—2018. <i>Sexually Transmitted Diseases</i> , 2021, 48, 709-713.	1.7	6
21	Pilot Study of Markers for High-grade Anal Dysplasia in a Southern Cohort From the Women's Interagency Human Immunodeficiency Virus Study. <i>Clinical Infectious Diseases</i> , 2020, 70, 1121-1128.	5.8	7
22	Cervical adenocarcinoma <i>in situ</i> : Human papillomavirus types and incidence trends in five states, 2008—2015. <i>International Journal of Cancer</i> , 2020, 146, 810-818.	5.1	34
23	Priming effect of bivalent and quadrivalent vaccine for HPV 31/33/45/52: an exploratory analysis from two clinical trials. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 590-594.	3.3	1
24	Prevalence, Incidence, and Clearance of Human Papillomavirus Types Covered by Current Vaccines in Men With Human Immunodeficiency Virus in the SUN Study. <i>Journal of Infectious Diseases</i> , 2020, 222, 234-242.	4.0	7
25	Effectiveness of 1, 2, and 3 Doses of Human Papillomavirus Vaccine Against High-Grade Cervical Lesions Positive for Human Papillomavirus 16 or 18. <i>American Journal of Epidemiology</i> , 2020, 189, 265-276.	3.4	20
26	Human Papillomavirus Vaccine Effectiveness Against HPV Infection: Evaluation of One, Two, and Three Doses. <i>Journal of Infectious Diseases</i> , 2020, 221, 910-918.	4.0	40
27	A prospective cohort study of immunogenicity of quadrivalent human papillomavirus vaccination among Alaska Native Children, Alaska, United States. <i>Vaccine</i> , 2020, 38, 6585-6591.	3.8	0
28	Duration of Cellular and Humoral Responses after Quadrivalent Human Papillomavirus Vaccination in Healthy Female Adults with or without Prior Type 16 and/or 18 Exposure. <i>Vaccines</i> , 2020, 8, 348.	4.4	4
29	Evaluation of serological assays to monitor antibody responses to single-dose HPV vaccines. <i>Vaccine</i> , 2020, 38, 5997-6006.	3.8	11
30	Sexual Mixing Patterns and Anal Human Papillomavirus Among Young Gay, Bisexual, and Other Men Who Have Sex With Men and Transgender Women in 2 Cities in the United States, 2012—2014. <i>Sexually Transmitted Diseases</i> , 2020, 47, 473-480.	1.7	0
31	Vaccine Effectiveness Against Prevalent Anal and Oral Human Papillomavirus Infection Among Men Who Have Sex With Men—United States, 2016—2018. <i>Journal of Infectious Diseases</i> , 2020, 222, 2052-2060.	4.0	26
32	Prevalence of HPV infection among sexually active adolescents and young adults in Brazil: The POP-Brazil Study. <i>Scientific Reports</i> , 2020, 10, 4920.	3.3	35
33	Bioinformatics Pipeline for Human Papillomavirus Short Read Genomic Sequences Classification Using Support Vector Machine. <i>Viruses</i> , 2020, 12, 710.	3.3	4
34	Delayed dosing intervals for quadrivalent human papillomavirus vaccine do not reduce antibody avidity. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 1802-1807.	3.3	1
35	An Isothermal, Multiplex Amplification Assay for Detection and Genotyping of Human Papillomaviruses in Formalin-Fixed, Paraffin-Embedded Tissues. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 419-428.	2.8	22
36	Comparison of a VLP-based and GST-based multiplex immunoassay to detect vaccine-induced HPV-specific antibodies in first void urine. <i>Journal of Medical Virology</i> , 2020, 92, 3774-3783.	5.0	8

#	ARTICLE	IF	CITATIONS
37	Chlamydia Trachomatis and Human Papillomavirus Serostatus in Puerto Rican Women. Puerto Rico Health Sciences Journal, 2020, 39, 28-33.	0.2	1
38	Trends in High-grade Cervical Lesions and Cervical Cancer Screening in 5 States, 2008–2015. Clinical Infectious Diseases, 2019, 68, 1282-1291.	5.8	40
39	The effect of comorbid medical and psychiatric diagnoses on chronic fatigue syndrome. Annals of Medicine, 2019, 51, 371-378.	3.8	13
40	Declines in Vaccine-Type Human Papillomavirus Prevalence in Females Across Racial/Ethnic Groups: Data From a National Survey. Journal of Adolescent Health, 2019, 65, 715-722.	2.5	34
41	Simultaneous extraction of mRNA and microRNA from whole blood stabilized in tempus tubes. BMC Research Notes, 2019, 12, 39.	1.4	8
42	Declines in HPV vaccine type prevalence in women screened for cervical cancer in the United States: Evidence of direct and herd effects of vaccination. Vaccine, 2019, 37, 3918-3924.	3.8	34
43	Endometriosis as a Comorbid Condition in Chronic Fatigue Syndrome (CFS): Secondary Analysis of Data From a CFS Case-Control Study. Frontiers in Pediatrics, 2019, 7, 195.	1.9	17
44	Universal human papillomavirus typing by whole genome sequencing following target enrichment: evaluation of assay reproducibility and limit of detection. BMC Genomics, 2019, 20, 231.	2.8	11
45	Human papillomavirus DNA detection, p16INK4a, and oral cavity cancer in a U.S. population. Oral Oncology, 2019, 91, 92-96.	1.5	15
46	Trends in Human Papillomavirus Vaccine Types 16 and 18 in Cervical Precancers, 2008–2014. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 602-609.	2.5	65
47	Results of a Pilot Study of a Mail-Based Human Papillomavirus Self-Testing Program for Underscreened Women From Appalachian Ohio. Sexually Transmitted Diseases, 2019, 46, 185-190.	1.7	14
48	Transgender Women Have Higher Human Papillomavirus Prevalence Than Men Who Have Sex With Men—Two U.S. Cities, 2012–2014. Sexually Transmitted Diseases, 2019, 46, 657-662.	1.7	31
49	Seroprevalence of Human Papillomavirus 6/11/16/18 Among Self-identified Gay/Bisexual Men Who Have Sex With Men, Men Who Have Sex With Women, and Females, United States, 2003–2010. Clinical Infectious Diseases, 2019, 69, 1011-1018.	5.8	8
50	Antibody persistence after a single dose of quadrivalent HPV vaccine and the effect of a dose of nonavalent vaccine given 3-8 years later – an exploratory study. Human Vaccines and Immunotherapeutics, 2019, 15, 503-507.	3.3	7
51	Estimated Number of Cases of High-Grade Cervical Lesions Diagnosed Among Women – United States, 2008 and 2016. Morbidity and Mortality Weekly Report, 2019, 68, 337-343.	15.1	55
52	Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices. Morbidity and Mortality Weekly Report, 2019, 68, 698-702.	15.1	585
53	Evaluation of NanoString Technology for Detection and Genotyping of Human Papillomavirus (HPV). FASEB Journal, 2019, 33, lb55.	0.5	0
54	Comparing Human Papillomavirus Prevalence in Rectal and Anal Cancer Using US Cancer Registries, 2014-2015. Journal of Registry Management, 2019, 46, 128-132.	0.1	0

#	ARTICLE	IF	CITATIONS
55	Risk Factors for Oral Human Papillomavirus Infection Among Young Men Who Have Sex With Menâ€”2 Cities, United States, 2012â€”2014. <i>Sexually Transmitted Diseases</i> , 2018, 45, 660-665.	1.7	14
56	Prevalence and Incidence of Anal and Cervical High-Risk Human Papillomavirus (HPV) Types Covered by Current HPV Vaccines Among HIV-Infected Women in the SUN Study. <i>Journal of Infectious Diseases</i> , 2018, 217, 1544-1552.	4.0	17
57	Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development. <i>Vaccine</i> , 2018, 36, 4792-4799.	3.8	60
58	Antibody responses among adolescent females receiving two or three quadrivalent human papillomavirus vaccine doses at standard and prolonged intervals. <i>Vaccine</i> , 2018, 36, 881-889.	3.8	8
59	Prevalence of Genital Human Papillomavirus Among Sexually Experienced Males and Females Aged 14â€”59 Years, United States, 2013â€”2014. <i>Journal of Infectious Diseases</i> , 2018, 217, 869-877.	4.0	39
60	Association of chronic fatigue syndrome with premature telomere attrition. <i>Journal of Translational Medicine</i> , 2018, 16, 44.	4.4	11
61	Population-Based Assessment of HPV Genotype-Specific Cervical Cancer Survival: CDC Cancer Registry Sentinel Surveillance System. <i>JNCI Cancer Spectrum</i> , 2018, 2, .	2.9	10
62	Trends in High-Grade Cervical Cancer Precursors in the Human Papillomavirus Vaccine Era. <i>American Journal of Preventive Medicine</i> , 2018, 55, 19-25.	3.0	11
63	Seroprevalence of Human Papillomavirus (HPV) Type 6, 11, 16, 18, by Anatomic Site of HPV Infection, in Women Aged 16-64 Years living in the Metropolitan Area of San Juan, Puerto Rico. <i>Puerto Rico Health Sciences Journal</i> , 2018, 37, 26-31.	0.2	3
64	Precision Medicine Requires Precision Laboratories. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 226-229.	2.8	2
65	Pathobiology of human papillomaviruses in human immunodeficiency virus â€” Infected persons. <i>Seminars in Diagnostic Pathology</i> , 2017, 34, 364-370.	1.5	5
66	Prevalence of Genital Human Papillomavirus in Males, United States, 2013â€”2014. <i>Journal of Infectious Diseases</i> , 2017, 215, 1070-1079.	4.0	66
67	Description of a novel multiplex avidity assay for evaluating HPV antibodies. <i>Journal of Immunological Methods</i> , 2017, 447, 31-36.	1.4	7
68	Concordance Between Anal and Oral Human Papillomavirus Infections Among Young Men Who have Sex With Men. <i>Journal of Infectious Diseases</i> , 2017, 215, 1832-1835.	4.0	16
69	Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study. <i>American Journal of Epidemiology</i> , 2017, 185, 617-626.	3.4	30
70	Universal Human Papillomavirus Typing Assay: Whole-Genome Sequencing following Target Enrichment. <i>Journal of Clinical Microbiology</i> , 2017, 55, 811-823.	3.9	16
71	Antibody response to human papillomavirus vaccination and natural exposure in individuals with Fanconi Anemia. <i>Vaccine</i> , 2017, 35, 6712-6719.	3.8	3
72	Surveillance of high-grade cervical cancer precursors (CIN III/AIS) in four population-based cancer registries, United States, 2009â€”2012. <i>Preventive Medicine</i> , 2017, 103, 60-65.	3.4	22

#	ARTICLE	IF	CITATIONS
73	Prevalence of Human Papillomavirus Among Females After Vaccine Introduction—National Health and Nutrition Examination Survey, United States, 2003–2014. <i>Journal of Infectious Diseases</i> , 2017, 216, 594-603.	4.0	122
74	Evaluation of the Vulvar Cancer Histology Code Reported by Central Cancer Registries: Importance in Epidemiology. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 139-143.	2.5	9
75	CDC Activities for Improving Implementation of Human Papillomavirus Vaccination, Cervical Cancer Screening, and Surveillance Worldwide. <i>Emerging Infectious Diseases</i> , 2017, 23, .	4.3	14
76	Serum Immune Profiling for Early Detection of Cervical Disease. <i>Theranostics</i> , 2017, 7, 3814-3823.	10.0	17
77	Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes. <i>Emerging Infectious Diseases</i> , 2016, 22, 1732-1740.	4.3	77
78	Label-Free and Continuous-Flow Ferrohydrodynamic Separation of HeLa Cells and Blood Cells in Biocompatible Ferrofluids. <i>Advanced Functional Materials</i> , 2016, 26, 3990-3998.	14.9	77
79	Two vs Three Doses of Human Papillomavirus Vaccine. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 2370.	7.4	12
80	Validation of a standardized extraction method for formalin-fixed paraffin-embedded tissue samples. <i>Journal of Clinical Virology</i> , 2016, 80, 36-39.	3.1	26
81	Prevalence of 9-Valent Human Papillomavirus Types by Race/Ethnicity in the Prevacine Era, United States, 2003–2006. <i>Sexually Transmitted Diseases</i> , 2016, 43, 633-636.	1.7	8
82	Monitoring for Human Papillomavirus Vaccine Impact Among Gay, Bisexual, and Other Men Who Have Sex With Men—United States, 2012–2014. <i>Journal of Infectious Diseases</i> , 2016, 214, 689-696.	4.0	48
83	Prevalence of HPV After Introduction of the Vaccination Program in the United States. <i>Pediatrics</i> , 2016, 137, e20151968.	2.1	262
84	Response to Pendleton et al. regarding reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States. <i>Vaccine</i> , 2016, 34, 201.	3.8	3
85	p16(INK4A) expression in invasive laryngeal cancer. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2016, 2, 52-55.	4.5	26
86	Seroprevalence of 9 Human Papillomavirus Types in the United States, 2005–2006. <i>Journal of Infectious Diseases</i> , 2016, 213, 191-198.	4.0	42
87	Incidence and Predictors of Abnormal Anal Cytology Findings Among HIV-Infected Adults Receiving Contemporary Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2016, 213, 351-360.	4.0	12
88	CDC Grand Rounds: Chronic Fatigue Syndrome — Advancing Research and Clinical Education. <i>Morbidity and Mortality Weekly Report</i> , 2016, 65, 1434-1438.	15.1	29
89	Assessment of ME/CFS (Myalgic Encephalomyelitis/Chronic Fatigue Syndrome): A Case Study for Health Care Providers. <i>MedEdPORTAL: the Journal of Teaching and Learning Resources</i> , 2016, 12, 10527.	1.2	0
90	Population-based trends in high-grade cervical lesions in the early human papillomavirus vaccine era in the United States. <i>Cancer</i> , 2015, 121, 2775-2781.	4.1	44

#	ARTICLE	IF	CITATIONS
91	Early menopause and other gynecologic risk indicators for chronic fatigue syndrome in women. <i>Menopause</i> , 2015, 22, 826-834.	2.0	17
92	Monitoring Effect of Human Papillomavirus Vaccines in US Population, Emerging Infections Program, 2008-2012. <i>Emerging Infectious Diseases</i> , 2015, 21, 1557-1561.	4.3	18
93	Human papillomavirus genotype and oropharynx cancer survival in the United States of America. <i>European Journal of Cancer</i> , 2015, 51, 2759-2767.	2.8	80
94	Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States - 2008-2012. <i>Vaccine</i> , 2015, 33, 1608-1613.	3.8	101
95	Pathway-focused genetic evaluation of immune and inflammation related genes with chronic fatigue syndrome. <i>Human Immunology</i> , 2015, 76, 553-560.	2.4	30
96	HPV Type Attribution in High-Grade Cervical Lesions: Assessing the Potential Benefits of Vaccines in a Population-Based Evaluation in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 393-399.	2.5	51
97	US Assessment of HPV Types in Cancers: Implications for Current and 9-Valent HPV Vaccines. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv086.	6.3	550
98	Oral Human Papillomavirus Is Common in Individuals with Fanconi Anemia. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 864-872.	2.5	23
99	Antibody responses among adolescent females receiving the quadrivalent HPV vaccine series corresponding to standard or non-standard dosing intervals. <i>Vaccine</i> , 2015, 33, 1953-1958.	3.8	10
100	Is vaccine type seropositivity a marker for human papillomavirus vaccination? National Health and Nutrition Examination Survey, 2003-2010. <i>International Journal of Infectious Diseases</i> , 2015, 33, 137-141.	3.3	9
101	Reduction in Human Papillomavirus Vaccine Type Prevalence Among Young Women Screened for Cervical Cancer in an Integrated US Healthcare Delivery System in 2007 and 2012-2013. <i>Journal of Infectious Diseases</i> , 2015, 212, 1970-1975.	4.0	33
102	Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. <i>Morbidity and Mortality Weekly Report</i> , 2015, 64, 300-4.	15.1	581
103	Decreased Basal Ganglia Activation in Subjects with Chronic Fatigue Syndrome: Association with Symptoms of Fatigue. <i>PLoS ONE</i> , 2014, 9, e98156.	2.5	66
104	Human Papillomavirus Prevalence in Oropharyngeal Cancer before Vaccine Introduction, United States. <i>Emerging Infectious Diseases</i> , 2014, 20, 822-828.	4.3	88
105	Overview of the CDC Cervical Cancer (Cx3) Study: An Educational Intervention of HPV Testing for Cervical Cancer Screening. <i>Journal of Women's Health</i> , 2014, 23, 197-203.	3.3	15
106	Prevalence of Cervical and Oral Human Papillomavirus Infections Among US Women. <i>Journal of Infectious Diseases</i> , 2014, 209, 1739-1743.	4.0	50
107	Human Papillomavirus Genotype Prevalence in Invasive Penile Cancers from a Registry-Based United States Population. <i>Frontiers in Oncology</i> , 2014, 4, 9.	2.8	48
108	Pre-vaccine era human papillomavirus types 6, 11, 16 and 18 seropositivity in the USA, National Health and Nutrition Examination Surveys, 2003-2006: Table A1. <i>Sexually Transmitted Infections</i> , 2014, 90, 505-508.	1.9	21

#	ARTICLE	IF	CITATIONS
109	Prevalence of Human Papillomavirus Types in Invasive Cervical Cancers From 7 US Cancer Registries Before Vaccine Introduction. <i>Journal of Lower Genital Tract Disease</i> , 2014, 18, 182-189.	1.9	62
110	Human Papillomavirus Genotype Prevalence in Invasive Vaginal Cancer From a Registry-Based Population. <i>Obstetrics and Gynecology</i> , 2014, 123, 817-821.	2.4	45
111	Would Young Women Attending Sexually Transmitted Disease Clinics Benefit From Human Papillomavirus Vaccination? An Assessment of Human Papillomavirus DNA and Seropositivity From Human Papillomavirus Sentinel Surveillance, 2003-2005. <i>Sexually Transmitted Diseases</i> , 2014, 41, 46-49.	1.7	2
112	Reply to Groner et al and Pei et al. <i>Journal of Infectious Diseases</i> , 2014, 209, 1304-1305.	4.0	0
113	Urine-based human papillomavirus DNA testing as a screening tool for cervical cancer in high-risk women. <i>International Journal of Gynecology and Obstetrics</i> , 2014, 124, 151-155.	2.3	16
114	Population-based surveillance for cervical cancer precursors in three central cancer registries, United States 2009. <i>Cancer Causes and Control</i> , 2014, 25, 571-581.	1.8	15
115	Type-specific HPV and Pap test results among low-income, underserved women: providing insights into management strategies. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 211, 354.e1-354.e6.	1.3	7
116	Chronic fatigue syndrome: the current status and future potentials of emerging biomarkers. <i>Fatigue: Biomedicine, Health and Behavior</i> , 2014, 2, 93-109.	1.9	28
117	Human papilloma virions in the laboratory. <i>Journal of Clinical Virology</i> , 2014, 61, 196-198.	3.1	3
118	Human Papillomavirus Prevalence in Invasive Laryngeal Cancer in the United States. <i>PLoS ONE</i> , 2014, 9, e115931.	2.5	41
119	CDC grand rounds: Reducing the burden of HPV-associated cancer and disease. <i>Morbidity and Mortality Weekly Report</i> , 2014, 63, 69-72.	15.1	56
120	Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Recommendations and Reports</i> , 2014, 63, 1-30.	61.1	387
121	Evaluation of genital self-sampling methods for HPV detection in males. <i>Journal of Clinical Virology</i> , 2013, 58, 168-175.	3.1	12
122	Can clinical tests help monitor human papillomavirus vaccine impact?. <i>International Journal of Cancer</i> , 2013, 133, 1101-1106.	5.1	11
123	Modeling the impact of quadrivalent HPV vaccination on the incidence of Pap test abnormalities in the United States. <i>Vaccine</i> , 2013, 31, 3019-3024.	3.8	13
124	Reduction in Human Papillomavirus (HPV) Prevalence Among Young Women Following HPV Vaccine Introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. <i>Journal of Infectious Diseases</i> , 2013, 208, 385-393.	4.0	456
125	Population Impact of HPV Vaccines: Summary of Early Evidence. <i>Journal of Adolescent Health</i> , 2013, 53, 679-682.	2.5	63
126	A pilot registry of unexplained fatiguing illnesses and chronic fatigue syndrome. <i>BMC Research Notes</i> , 2013, 6, 309.	1.4	5

#	ARTICLE	IF	CITATIONS
127	Prevalence of HPV types in cervical specimens from an integrated healthcare delivery system: baseline assessment to measure HPV vaccine impact. <i>Cancer Causes and Control</i> , 2013, 24, 403-407.	1.8	11
128	Human Papillomavirus Prevalence in Invasive Anal Cancers in the United States Before Vaccine Introduction. <i>Journal of Lower Genital Tract Disease</i> , 2013, 17, 397-403.	1.9	37
129	Multiscale analysis of heart rate variability in non-stationary environments. <i>Frontiers in Physiology</i> , 2013, 4, 119.	2.8	21
130	Acute Psychosocial Stress-Mediated Changes in the Expression and Methylation of Perforin in Chronic Fatigue Syndrome. <i>Genetics & Epigenetics</i> , 2013, 5, GEG.S10944.	2.5	11
131	Individual and geographic disparities in human papillomavirus types 16/18 in high-grade cervical lesions. <i>Cancer</i> , 2013, 119, 3052-3058.	4.1	44
132	HPV genotypes detected in cervical cancers from Alaska Native women, 1980-2007. <i>International Journal of Circumpolar Health</i> , 2013, 72, 21115.	1.2	4
133	HPV Prevalence among Women from Appalachia: Results from the CARE Project. <i>PLoS ONE</i> , 2013, 8, e74276.	2.5	18
134	Genital human papillomaviruses among women of reproductive age in Jamaica. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 2013, 33, 159-165.	1.1	17
135	Controlling for Population Variances in Health and Exposure Risk Using Randomized Matrix Based Mathematical Modeling. <i>Lecture Notes in Computer Science</i> , 2013, , 184-192.	1.3	0
136	Human Papillomavirus Antibody Reference Reagents for Use in Postvaccination Surveillance Serology. <i>Vaccine Journal</i> , 2012, 19, 449-451.	3.1	17
137	Age-Group Differences in Human Papillomavirus Types and Cofactors for Cervical Intraepithelial Neoplasia 3 among Women Referred to Colposcopy. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 111-121.	2.5	16
138	Human Papillomavirus Genotypes in High-Grade Cervical Lesions in the United States. <i>Journal of Infectious Diseases</i> , 2012, 206, 1878-1886.	4.0	58
139	Performance of Commercial Reverse Line Blot Assays for Human Papillomavirus Genotyping. <i>Journal of Clinical Microbiology</i> , 2012, 50, 1539-1544.	3.9	25
140	Prevalence of Human Papillomavirus Types in Invasive Vulvar Cancers and Vulvar Intraepithelial Neoplasia 3 in the United States Before Vaccine Introduction. <i>Journal of Lower Genital Tract Disease</i> , 2012, 16, 471-479.	1.9	58
141	Continuous-flow ferrohydrodynamic sorting of particles and cells in microfluidic devices. <i>Microfluidics and Nanofluidics</i> , 2012, 13, 645-654.	2.2	99
142	Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions. <i>Vaccine</i> , 2012, 31, 109-113.	3.8	74
143	International collaborative proficiency study of Human Papillomavirus type 16 serology. <i>Vaccine</i> , 2012, 30, 294-299.	3.8	22
144	Minimum data elements for research reports on CFS. <i>Brain, Behavior, and Immunity</i> , 2012, 26, 401-406.	4.1	25

#	ARTICLE	IF	CITATIONS
145	HPV Genotypes in High Grade Cervical Lesions and Invasive Cervical Carcinoma as Detected by Two Commercial DNA Assays, North Carolina, 2001–2006. PLoS ONE, 2012, 7, e34044.	2.5	24
146	Sensitive and Specific Peak Detection for SELDI-TOF Mass Spectrometry Using a Wavelet/Neural-Network Based Approach. PLoS ONE, 2012, 7, e48103.	2.5	6
147	Oral sampling and human papillomavirus genotyping in HIV-infected patients. Journal of Oral Pathology and Medicine, 2012, 41, 288-291.	2.7	29
148	Patterns of cellular and HPV 16 methylation as biomarkers for cervical neoplasia. Journal of Virological Methods, 2012, 184, 84-92.	2.1	22
149	The HPV vaccine impact monitoring project (HPV-IMPACT): assessing early evidence of vaccination impact on HPV-associated cervical cancer precursor lesions. Cancer Causes and Control, 2012, 23, 281-288.	1.8	34
150	A real-time PCR assay for HPV52 detection and viral load quantification. Clinical Laboratory, 2012, 58, 61-6.	0.5	33
151	Efficient DNA Extraction for HPV Genotyping in Formalin-Fixed, Paraffin-Embedded Tissues. Journal of Molecular Diagnostics, 2011, 13, 377-381.	2.8	95
152	Lack of HPV 16 and 18 detection in serum of colposcopy clinic patients. Journal of Clinical Virology, 2011, 50, 342-344.	3.1	1
153	Human Papillomavirus Infection and Cytologic Abnormalities of the Anus and Cervix Among HIV-Infected Women in the Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (The SUN Study). Sexually Transmitted Diseases, 2011, 38, 253-259.	1.7	94
154	Functional Genomics of Serotonin Receptor 2A (HTR2A): Interaction of Polymorphism, Methylation, Expression and Disease Association. NeuroMolecular Medicine, 2011, 13, 66-76.	3.4	62
155	Identification of Phosphoglycerate Kinase 1 (PGK1) as a reference gene for quantitative gene expression measurements in human blood RNA. BMC Research Notes, 2011, 4, 324.	1.4	45
156	Impact of HPV Assay on Observed Population Prevalence. Diagnostic Molecular Pathology, 2011, 20, 101-104.	2.1	6
157	The association of current hormonal contraceptive use with type-specific HPV detection. Sexually Transmitted Infections, 2011, 87, 385-388.	1.9	11
158	Anogenital Human Papillomavirus in Sexually Abused and Nonabused Children: A Multicenter Study. Pediatrics, 2011, 128, e658-e665.	2.1	40
159	Convergent Genomic Studies Identify Association of GRIK2 and NPAS2 with Chronic Fatigue Syndrome. Neuropsychobiology, 2011, 64, 183-194.	1.9	60
160	Prevalence of Genital Human Papillomavirus Among Females in the United States, the National Health and Nutrition Examination Survey, 2003–2006. Journal of Infectious Diseases, 2011, 204, 566-573.	4.0	333
161	Human Papillomavirus (HPV) 6, 11, 16, and 18 Prevalence Among Females in the United States—National Health and Nutrition Examination Survey, 2003–2006: Opportunity to Measure HPV Vaccine Impact?. Journal of Infectious Diseases, 2011, 204, 562-565.	4.0	60
162	Characterization of the Human Cervical Mucous Proteome. Clinical Proteomics, 2010, 6, 18-28.	2.1	32

#	ARTICLE	IF	CITATIONS
163	Implementation of exon arrays: alternative splicing during T-cell proliferation as determined by whole genome analysis. <i>BMC Genomics</i> , 2010, 11, 496.	2.8	13
164	Assessing the relationship between HIV infection and cervical cancer in CÔte d'Ivoire: A case-control study. <i>BMC Infectious Diseases</i> , 2010, 10, 242.	2.9	44
165	In Situ Hybridization. , 2010, , 71-79.		1
166	A Response to Jason et al. (2009), "Evaluating the Centers for Disease Control's Empirical Chronic Fatigue Syndrome Case Definition" Journal of Disability Policy Studies, 2010, 20, 229-232.	1.5	4
167	Differences and changes in human papillomavirus type 16 variant status in human immunodeficiency virus-positive adults are not uncommon. <i>Journal of General Virology</i> , 2010, 91, 2068-2072.	2.9	8
168	Post-licensure monitoring of HPV vaccine in the United States. <i>Vaccine</i> , 2010, 28, 4731-4737.	3.8	91
169	Invasive and In Situ Cervical Cancer Reported to the Vaccine Adverse Event Reporting System (VAERS). <i>Journal of Women's Health</i> , 2010, 19, 365-370.	3.3	9
170	Evaluation of the Rapid BioStar Optical Immunoassay for Detection of <i>Chlamydia trachomatis</i> in Adolescent Women. <i>Journal of Clinical Microbiology</i> , 2009, 47, 215-216.	3.9	23
171	Seroprevalence of Human Papillomavirus Types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004. <i>Journal of Infectious Diseases</i> , 2009, 200, 1059-1067.	4.0	163
172	Primary and Secondary Prevention of Cervical Cancer--Opportunities and Challenges. <i>Journal of the National Cancer Institute</i> , 2009, 101, 439-440.	6.3	6
173	An evaluation of exclusionary medical/psychiatric conditions in the definition of chronic fatigue syndrome. <i>BMC Medicine</i> , 2009, 7, 57.	5.5	28
174	Optimization of SELDI-TOF protein profiling for analysis of cervical mucous. <i>Journal of Proteomics</i> , 2009, 71, 637-646.	2.4	21
175	Multicenter Study of Nucleic Acid Amplification Tests for Detection of <i>Chlamydia trachomatis</i> and <i>Neisseria gonorrhoeae</i> in Children Being Evaluated for Sexual Abuse. <i>Pediatric Infectious Disease Journal</i> , 2009, 28, 608-613.	2.0	81
176	Human papillomavirus and molecular considerations for cancer risk. <i>Cancer</i> , 2008, 113, 2981-2994.	4.1	57
177	Toward using National Cancer Surveillance data for preventing and controlling cervical and other human papillomavirus-associated cancers in the US. <i>Cancer</i> , 2008, 113, 2837-2840.	4.1	10
178	Type-specific reproducibility of the Roche linear array HPV genotyping test. <i>Journal of Clinical Virology</i> , 2008, 42, 412-414.	3.1	30
179	Human Papillomavirus Infection and Cervical Cytology in Women Screened for Cervical Cancer in the United States, 2003-2005. <i>Annals of Internal Medicine</i> , 2008, 148, 493.	3.9	128
180	Seroepidemiology of Human Papillomavirus Type 11 in the United States: Results From the Third National Health and Nutrition Examination Survey, 1991-1994. <i>Sexually Transmitted Diseases</i> , 2008, 35, 298-303.	1.7	21

#	ARTICLE	IF	CITATIONS
181	Alterations in Diurnal Salivary Cortisol Rhythm in a Population-Based Sample of Cases With Chronic Fatigue Syndrome. <i>Psychosomatic Medicine</i> , 2008, 70, 298-305.	2.0	101
182	Evaluation of RNA Markers for Early Detection of Cervical Neoplasia in Exfoliated Cervical Cells. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 295-301.	2.5	8
183	Prevalence of HPV Infection Among Females in the United States. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 813.	7.4	1,286
184	Cervical Cancer Incidence in a Prevaccine Era in the United States, 1998–2002. <i>Obstetrics and Gynecology</i> , 2007, 109, 360-370.	2.4	111
185	Effect of storage temperatures on the stability of cytokines in cervical mucous. <i>Cytokine</i> , 2007, 37, 176-179.	3.2	23
186	Perception versus polysomnographic assessment of sleep in CFS and non-fatigued control subjects: results from a population-based study. <i>BMC Neurology</i> , 2007, 7, 40.	1.8	44
187	Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Recommendations and Reports</i> , 2007, 56, 1-24.	61.1	614
188	DNA and RNA References for qRT-PCR Assays in Exfoliated Cervical Cells. <i>Journal of Molecular Diagnostics</i> , 2006, 8, 113-118.	2.8	58
189	Effect of Specimen Order on Chlamydia trachomatis and Neisseria gonorrhoeae Test Performance and Adequacy of Papanicolaou Smear. <i>Journal of Pediatric and Adolescent Gynecology</i> , 2006, 19, 23-30.	0.7	9
190	Coping styles in people with chronic fatigue syndrome identified from the general population of Wichita, KS. <i>Journal of Psychosomatic Research</i> , 2006, 60, 567-573.	2.6	36
191	Exploration of statistical dependence between illness parameters using the entropy correlation coefficient. <i>Pharmacogenomics</i> , 2006, 7, 421-428.	1.3	11
192	Human papillomavirus type 16 variant assignment by pyrosequencing. <i>Journal of Virological Methods</i> , 2006, 136, 166-170.	2.1	19
193	Quantitation of site-specific HPV 16 DNA methylation by pyrosequencing. <i>Journal of Virological Methods</i> , 2006, 138, 170-176.	2.1	28
194	Sleep characteristics of persons with chronic fatigue syndrome and non-fatigued controls: results from a population-based study. <i>BMC Neurology</i> , 2006, 6, 41.	1.8	63
195	Human papillomavirus in amniotic fluid. <i>BMC Pregnancy and Childbirth</i> , 2006, 6, 28.	2.4	8
196	Early Adverse Experience and Risk for Chronic Fatigue Syndrome. <i>Archives of General Psychiatry</i> , 2006, 63, 1258.	12.3	198
197	Longitudinal Measures of Human Papillomavirus 6 and 11 Viral Loads and Antibody Response in Children With Recurrent Respiratory Papillomatosis. <i>JAMA Otolaryngology</i> , 2006, 132, 711.	1.2	43
198	Gene expression correlates of unexplained fatigue. <i>Pharmacogenomics</i> , 2006, 7, 395-405.	1.3	29

#	ARTICLE	IF	CITATIONS
199	Simultaneous Amplification and Identification of 25 Human Papillomavirus Types with Tempex Technology. <i>Journal of Clinical Microbiology</i> , 2006, 44, 4157-4162.	3.9	100
200	Identifying illness parameters in fatiguing syndromes using classical projection methods. <i>Pharmacogenomics</i> , 2006, 7, 407-419.	1.3	43
201	The Effect of Correct and Consistent Condom Use on Chlamydial and Gonococcal Infection Among Urban Adolescents. <i>JAMA Pediatrics</i> , 2005, 159, 536.	3.0	64
202	Gene expression profile of cervical tissue compared to exfoliated cells: Impact on biomarker discovery. <i>BMC Genomics</i> , 2005, 6, 64.	2.8	18
203	Chronic Fatigue Syndrome – A clinically empirical approach to its definition and study. <i>BMC Medicine</i> , 2005, 3, 19.	5.5	225
204	Human papillomavirus type 16 E2 and E6/E7 variants. <i>Gynecologic Oncology</i> , 2005, 96, 695-700.	1.4	30
205	Correlates of cervical mucosal antibodies to human papillomavirus 16: Results from a case control study. <i>Gynecologic Oncology</i> , 2005, 99, S262-S268.	1.4	20
206	Epidemiologic and viral factors associated with cervical neoplasia in HPV-16-positive women. <i>International Journal of Cancer</i> , 2005, 115, 114-120.	5.1	49
207	Exercise responsive genes measured in peripheral blood of women with chronic fatigue syndrome and matched control subjects. <i>BMC Physiology</i> , 2005, 5, 5.	3.6	57
208	Psychometric properties of the CDC Symptom Inventory for assessment of Chronic Fatigue Syndrome. <i>Population Health Metrics</i> , 2005, 3, 8.	2.7	143
209	Seroprevalence of Human Papillomavirus Type 16 in Children. <i>Journal of Infectious Diseases</i> , 2005, 191, 1817-1819.	4.0	43
210	Association of Chlamydia trachomatis with Persistence of High-Risk Types of Human Papillomavirus in a Cohort of Female Adolescents. <i>American Journal of Epidemiology</i> , 2005, 162, 668-675.	3.4	163
211	Gene expression profiling of dysplastic differentiation in cervical epithelial cells harboring human papillomavirus 16. <i>Genomics</i> , 2005, 85, 727-738.	2.9	5
212	Recurrent respiratory papillomatosis: bright prospects for vaccine-based prevention. <i>Papillomavirus Report</i> , 2005, 16, 333-338.	0.2	7
213	Molecular Markers for Early Detection of Cervical Neoplasia. <i>Disease Markers</i> , 2004, 20, 103-116.	1.3	12
214	Molecular Characterization of Human Papillomaviruses by PCR and <i>In Situ</i> Hybridization. , 2004, 97, 159-180.		0
215	Epidemiology of Human Papillomavirus Infection and Abnormal Cytologic Test Results in an Urban Adolescent Population. <i>Journal of Infectious Diseases</i> , 2004, 189, 46-50.	4.0	123
216	Short Duration of Elevated vIRF-1 Expression during Lytic Replication of Human Herpesvirus 8 Limits Its Ability To Block Antiviral Responses Induced by Alpha Interferon in BCBL-1 Cells. <i>Journal of Virology</i> , 2004, 78, 6621-6635.	3.4	49

#	ARTICLE	IF	CITATIONS
217	Sleep assessment in a population-based study of chronic fatigue syndrome. <i>BMC Neurology</i> , 2004, 4, 6.	1.8	57
218	Differential-display PCR of peripheral blood for biomarker discovery in chronic fatigue syndrome. <i>Journal of Molecular Medicine</i> , 2004, 82, 750-755.	3.9	36
219	Regional distribution of fatiguing illnesses in the United States: a pilot study. <i>Population Health Metrics</i> , 2004, 2, 1.	2.7	42
220	Exploration of neuroendocrine and immune gene expression in peripheral blood mononuclear cells. <i>Molecular Brain Research</i> , 2004, 129, 193-197.	2.3	21
221	Factor analysis of symptoms among subjects with unexplained chronic fatigue. <i>Journal of Psychosomatic Research</i> , 2004, 56, 171-178.	2.6	70
222	Human Papillomavirus and Cervical Cancer. <i>Emerging Infectious Diseases</i> , 2004, , .	4.3	1
223	Molecular quality of exfoliated cervical cells: implications for molecular epidemiology and biomarker discovery. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 492-6.	2.5	13
224	The effect of time interval between referral and colposcopy on detection of human papillomavirus DNA and on outcome of biopsy. <i>American Journal of Obstetrics and Gynecology</i> , 2003, 188, 932-937.	1.3	8
225	Identification of ambiguities in the 1994 chronic fatigue syndrome research case definition and recommendations for resolution. <i>BMC Health Services Research</i> , 2003, 3, 25.	2.2	413
226	Bioelectronic DNA detection of human papillomaviruses using eSensor [®] : a model system for detection of multiple pathogens. <i>BMC Infectious Diseases</i> , 2003, 3, 12.	2.9	35
227	A population-based study of the clinical course of chronic fatigue syndrome. <i>Health and Quality of Life Outcomes</i> , 2003, 1, 49.	2.4	90
228	Integration of gene expression, clinical, and epidemiologic data to characterize Chronic Fatigue Syndrome. <i>Journal of Translational Medicine</i> , 2003, 1, 10.	4.4	53
229	Global amplification of sense RNA: a novel method to replicate and archive mRNA for gene expression analysis. <i>Genomics</i> , 2003, 82, 491-497.	2.9	12
230	Prevalence and Incidence of Chronic Fatigue Syndrome in Wichita, Kansas. <i>Archives of Internal Medicine</i> , 2003, 163, 1530.	3.8	385
231	National Registry for Juvenile-Onset Recurrent Respiratory Papillomatosis. <i>JAMA Otolaryngology</i> , 2003, 129, 976.	1.2	173
232	Predictors of Remission in Juvenile-Onset Recurrent Respiratory Papillomatosis. <i>JAMA Otolaryngology</i> , 2003, 129, 1275.	1.2	36
233	Impact of RNA extraction from limited samples on microarray results. <i>BioTechniques</i> , 2003, 35, 968-973.	1.8	21
234	Optimization of a Human Papillomavirus-Specific Enzyme-Linked Immunosorbent Assay. <i>Vaccine Journal</i> , 2002, 9, 577-582.	3.1	16

#	ARTICLE	IF	CITATIONS
235	Seroprevalence of Human Papillomavirus Type 16 Infection in the United States. <i>Journal of Infectious Diseases</i> , 2002, 186, 1396-1402.	4.0	192
236	Utility of the Blood for Gene Expression Profiling and Biomarker Discovery in Chronic Fatigue Syndrome. <i>Disease Markers</i> , 2002, 18, 193-199.	1.3	73
237	Assessment of Normal Variability in Peripheral Blood Gene Expression. <i>Disease Markers</i> , 2002, 18, 201-206.	1.3	14
238	Analysis of 16S rRNA gene sequences and circulating cell-free DNA from plasma of chronic fatigue syndrome and non-fatigued subjects. <i>BMC Microbiology</i> , 2002, 2, 39.	3.3	24
239	Modifying Differential Display Polymerase Chain Reaction to Detect Relative Changes in Gene Expression Profiles. <i>Analytical Biochemistry</i> , 2002, 306, 343-346.	2.4	8
240	Detection of Human Papillomaviruses by Polymerase Chain Reaction and In Situ Hybridization. , 2001, 49, 271-300.		0
241	Use of Real-Time Quantitative PCR to Validate the Results of cDNA Array and Differential Display PCR Technologies. <i>Methods</i> , 2001, 25, 443-451.	3.8	273
242	HUMAN PAPILOMAVIRUSES. <i>Obstetrics and Gynecology Clinics of North America</i> , 2001, 28, 653-666.	1.9	11
243	Validation of Array-Based Gene Expression Profiles by Real-Time (Kinetic) RT-PCR. <i>Journal of Molecular Diagnostics</i> , 2001, 3, 26-31.	2.8	280
244	Interphase Cytogenetic Analysis of 1q12 Satellite III DNA in Melanocytic Lesions. <i>American Journal of Dermatopathology</i> , 2001, 23, 176-180.	0.6	8
245	Real-time PCR-based fluorescent assay for quantitation of human papillomavirus types 6, 11, 16, and 18. <i>Molecular Diagnosis and Therapy</i> , 2001, 6, 39-47.	1.1	20
246	Improved detection of viral RNA isolated from liquid-based cytology samples. <i>Molecular Diagnosis and Therapy</i> , 2001, 6, 125-130.	1.1	21
247	Real-time PCR-based Fluorescent Assay for Quantitation of Human Papillomavirus Types 6, 11, 16, and 18. <i>Molecular Diagnosis and Therapy</i> , 2001, 6, 39-47.	1.1	44
248	Improved Detection of Viral RNA Isolated From Liquid-based Cytology Samples. <i>Molecular Diagnosis and Therapy</i> , 2001, 6, 125-130.	1.1	46
249	Human Papillomaviruses. , 2001, , 305-314.		0
250	Comparison of Human Papillomavirus Detection and Typing by Cycle Sequencing, Line Blotting, and Hybrid Capture. <i>Journal of Clinical Microbiology</i> , 2000, 38, 651-655.	3.9	133
251	In Situ Diagnosis of Human Papillomaviruses. <i>Clinics in Laboratory Medicine</i> , 2000, 20, 289-301.	1.4	23
252	Reproducibility of Alternative Probe Synthesis Approaches for Gene Expression Profiling with Arrays. <i>Journal of Molecular Diagnostics</i> , 2000, 2, 124-127.	2.8	47

#	ARTICLE	IF	CITATIONS
253	Chemiluminescent Analysis of Gene Expression on High-density Filter Arrays. Journal of Histochemistry and Cytochemistry, 1999, 47, 337-342.	2.5	31
254	An unusual cervical carcinoma showing exception to epitheliotropism of human papillomavirus. Human Pathology, 1999, 30, 483-485.	2.0	12
255	Human Papillomavirus (HPV) DNA Copy Number Is Dependent on Grade of Cervical Disease and HPV Type. Journal of Clinical Microbiology, 1999, 37, 1030-1034.	3.9	205
256	Characterization of RNA in cytologic samples preserved in a methanol-based collection solution*, **. Molecular Diagnosis and Therapy, 1998, 3, 67-72.	1.1	20
257	Detection of Human Papillomavirus in Archival Tissues: Comparison of In Situ Hybridization and Polymerase Chain Reaction. Journal of Histochemistry and Cytochemistry, 1998, 46, 535-540.	2.5	34
258	Association of human papillomavirus type 16 integration in the E2 gene with poor disease-free survival from cervical cancer. International Journal of Cancer, 1997, 74, 50-56.	5.1	106
259	In Situ Hybridization: Principles And Diagnostic Applications in Infection. Journal of Histotechnology, 1995, 18, 203-209.	0.5	11
260	Kaposi sarcoma presenting as a vulvar mass. Obstetrics and Gynecology, 1995, 86, 695-697.	2.4	10
261	Amplification of human papillomavirus types 16 and 18 in invasive cervical cancer. Human Pathology, 1995, 26, 676-681.	2.0	44
262	DNA Technology. Laboratory Medicine, 1994, 25, 675-676.	1.2	0
263	Latent epstein-barr virus infection is an unlikely event in the pathogenesis of immunoproliferative small intestinal disease. Cancer, 1994, 74, 1699-1705.	4.1	5
264	Application of a Manual Capillary Action Workstation to Colorimetric In Situ Hybridization. Journal of Histotechnology, 1993, 16, 33-38.	0.5	12
265	In Situ Hybridization for Human Papillomavirus DNA in Uterine Adenosquamous Carcinoma with Glassy Cell Features (Glassy Cell Carcinoma). American Journal of Clinical Pathology, 1992, 98, 180-187.	0.7	16
266	Avian model for 13-cis-retinoic acid embryopathy: Morphological characterization of ventricular septal defects. Teratology, 1992, 46, 533-539.	1.6	11
267	In situ and northern hybridizations. Cancer, 1992, 69, 1532-1535.	4.1	3
268	Association of human papillomavirus with penile carcinoma: A study using polymerase chain reaction and in situ hybridization. Human Pathology, 1991, 22, 908-913.	2.0	53
269	Automated Immunohistochemical Estrogen Receptor in Fixed Embedded Breast Carcinomas. American Journal of Clinical Pathology, 1991, 95, 335-339.	0.7	12
270	Non-hodgkin's lymphomas in patients with human immunodeficiency virus infection. Presence of epstein-barr virus by In situ hybridization, clinical presentation, and follow-up. Cancer, 1991, 68, 2460-2465.	4.1	41

#	ARTICLE	IF	CITATIONS
271	Avian model for 13-cis-retinoic acid embryopathy: Demonstration of neural crest related defects. <i>Teratology</i> , 1990, 41, 463-472.	1.6	31
272	Composite Hodgkin's and Non-Hodgkin's lymphoma in a patient with acquired immune deficiency syndrome. In-situ demonstration of Epstein-Barr virus. <i>Cancer</i> , 1990, 66, 796-800.	4.1	33
273	Malignant fibrous histiocytoma of the trachea. <i>Annals of Thoracic Surgery</i> , 1990, 50, 458-459.	1.3	15
274	In situ hybridization: Principles and practice. <i>Clinical Immunology Newsletter</i> , 1990, 10, 120-126.	0.1	3
275	Automated Immunohistochemical Estrogen Receptor in Fixed Embedded Breast Carcinomas: Comparison with Manual Immunohistochemistry on Frozen Tissues. <i>American Journal of Clinical Pathology</i> , 1989, 92, 669-672.	0.7	16
276	Automation of In situ Hybridization: Application of the Capillary Action Robotic Workstation. <i>Journal of Histotechnology</i> , 1988, 11, 253-258.	0.5	41
277	Immunocytochemistry is Automated: Development of A Robotic Workstation Based Upon the Capillary Action Principle. <i>Journal of Histotechnology</i> , 1988, 11, 165-183.	0.5	96
278	Viral Diagnosis by in situ Hybridization. <i>American Journal of Surgical Pathology</i> , 1986, 10, 1-8.	3.7	213
279	Synchronous carcinomas of the uterine corpus and ovary. <i>Gynecologic Oncology</i> , 1984, 19, 329-335.	1.4	103